Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when RIGL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRigel acquires FDA-approved breast cancer drug VEPPANU for $70M upfront plus milestones
Filed May 12, 2026 · Period ending May 11, 2026 · ~1 min read
Key Changes
-
high
Rigel acquired exclusive worldwide rights to VEPPANU (vepdegestrant), an FDA-approved treatment for ER+, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, giving the company an immediate commercial-stage oncology asset.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
The company will pay $70M upfront plus $15M upon transition completion, totaling $85M in near-term cash obligations, with up to $40M additional for development cost reimbursement during transition.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
Rigel faces up to $320M in contingent milestones (up to $60M regulatory, up to $260M sales-based) plus tiered royalties of mid-teens to mid-twenties percentages on net sales, which will significantly impact product margins.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
The agreement requires Hart-Scott-Rodino antitrust clearance before becoming effective, introducing regulatory timing uncertainty though such clearances are typically routine for pharmaceutical licensing deals.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
Summary
Rigel Pharmaceuticals has entered into a license agreement to acquire exclusive worldwide rights to VEPPANU (vepdegestrant), an FDA-approved treatment for a specific type of advanced breast cancer. This represents a significant strategic shift for Rigel, adding a commercial-stage oncology product to its portfolio with immediate revenue potential.
The drug is already approved in the United States for adults with ER+, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who have progressed after at least one line of endocrine therapy. The financial commitment is substantial.
Rigel will pay $70 million upfront plus $15 million upon completing transition activities, with up to $40 million more for development cost reimbursement—totaling approximately $125 million in near-term cash obligations. Beyond that, the company faces up to $320 million in contingent milestone payments and must pay tiered royalties ranging from mid-teens to mid-twenties percentages on net sales. These royalty rates will materially impact product margins, though the milestone payments are performance-contingent and spread over time. For retail investors, this acquisition transforms Rigel's profile by adding commercial revenue potential, but the heavy royalty burden and significant upfront cash requirements warrant attention to the company's balance sheet and cash runway. The deal remains subject to routine antitrust clearance.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
In connection with the transition of the Licensed Products, Pfizer will continue to be responsible for certain ongoing development activities, and Rigel has agreed to reimburse the Licensors for certain development costs and expenses incurred in connection with such activities, up to an aggregate amount of $40 million.
Rigel will reimburse up to $40 million for ongoing development costs that Pfizer continues to perform during the transition period. This is an additional near-term cash obligation beyond the upfront and transition payments, bringing total committed cash to approximately $125 million.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 9, 2026 · How we verify